KONEXElectrical Equipment447690

Aiobio

₩2,505 0.00%2026-11-18 close
Market Cap
₩6.9B
Turnover
₩0
Volume
0 shares
Shares out.
2.8M
PER
—
PBR
—
EPS
—
Dividend Yield
—

PER, PBR and dividend yield are calculated from the latest confirmed results (EPS, BPS, dividend per share) and the current share price · Prices as of the 2026-11-18 close

01

Report overview

Dental diagnostics growth, losses remain the hurdle

Aiobio is growing dental diagnostic device sales, but operating losses and capital impairment remain the core financial issues.

  1. 1

    Revenue for 2025 was KRW 3.4 billion, up 46.2% from KRW 2.3 billion in 2024.

  2. 2

    Operating loss narrowed to KRW 3.7 billion, while net loss widened to KRW 5.3 billion.

  3. 3

    Total equity at end-2025 stood at KRW -6.1 billion, leaving the company in a state of full capital impairment.

  4. 4

    FDA Class II clearance and a 100%-owned U.S. subsidiary widen the overseas base, but sales network and advertising costs are cited as drivers of losses.

  5. 5

    As of the March 2026 annual report, the company had selected a lead underwriter in September 2025 to pursue a transfer listing to KOSDAQ.

02

Business structure

Aiobio was founded in 2011 and changed its name in 2017. It is an oral disease diagnostic device maker. Its core products are the Curae Cam and Curae Pen oral imaging devices, which use quantitative light-induced fluorescence (QLF) to assist in diagnosing dental caries.

The company positions QBLISS, an ecosystem combining devices, a platform and analytics for quantitative bio-fluorescence based diagnostics, as the center of its business model.

In May 2021, QLF-based caries testing received a National Health Insurance coverage notice, and in February 2025 coverage was extended to children aged 15 and under, with testing frequency raised to once every three months.

In Korea, revenue has grown as the company built a sales system through dental clinics and expanded promotion. Its LINKDENS oral care software began a domestic pilot service in June 2024 and is expanding into public health areas such as rural mobile dental clinic programs.

Overseas, the company exported Qscan Plus to GSK Consumer Healthcare (now Haleon) in 2019 and obtained U.S. FDA Class II market clearance in September 2024. The U.S. sales base was restructured in fiscal 2025 into a 100%-owned subsidiary through a capital injection.

In competitive terms, the company presents its reimbursed QLF method as a differentiator for entry into the formal healthcare system. Founder and CEO Yoon Hong-cheol held 36.65% of issued shares as of June 30, 2025.

03

Recent trends

Based on 2025 results disclosed to DART, revenue reached KRW 3.4 billion, up 46.2% from KRW 2.3 billion in 2024. Over the same period, operating loss narrowed from KRW 4.5 billion to KRW 3.7 billion, while net loss widened from KRW 4.8 billion to KRW 5.3 billion.

The wider net loss reflects equity-method losses recognized for the first time and higher interest expenses versus 2024. Within selling and administrative expenses, advertising costs declined from the prior year.

Total equity at end-2025 was KRW -6.1 billion and total liabilities KRW 8.6 billion, leaving the company in full capital impairment. According to a corporate information provider, the current ratio recovered to 79.5% in 2025 after falling to 53.5% in 2024.

At the 15th annual general meeting held on March 31, 2026, financial statements, partial amendments to the articles of incorporation, and a stock option grant were all approved. The share price stood at KRW 2,400 on November 11, 2026, up 11.11% from the prior close, with trading value of 220,780 won. Market capitalization of about KRW 6.7 billion places the company among the smaller names on KONEX.

04

Outlook

The central question for the outlook is whether revenue growth translates into a smaller loss base. Revenue rose and operating loss narrowed in 2025, but the overseas sales network and advertising costs are still cited as loss drivers.

A technical analysis report by Seoul Credit Rating & Information presented expanded dental insurance coverage and the formal entry of non-face-to-face oral care as growth opportunities. That reading depends on whether overseas regulatory approvals convert into actual revenue.

The pace at which expanded domestic insurance coverage is adopted in dental clinics is the second checkpoint. Capital raising to resolve capital impairment is the most important variable.

With total equity at KRW -6.1 billion at end-2025, the outcome of any capital increase will be the starting point for assessing the balance sheet. The timing of the planned KOSDAQ transfer listing may also shift depending on listing requirements and funding plans.

The next checkpoints are quarterly revenue trends, the size of operating losses, the overseas revenue share, and capital raising disclosures.

05

Bull factors

Wider health insurance coverage

QLF-based caries testing received a National Health Insurance coverage notice in May 2021, and in February 2025 eligibility was extended to children aged 15 and under. Insurance coverage lowers the economic burden on dental clinics adopting the test.

A Seoul Credit Rating & Information technical report cited expanded dental insurance coverage as a growth opportunity. If testing frequency rises within the insurance framework, device usage and the revenue base could expand together.

Overseas clearances and export track record

The company obtained U.S. FDA Class II market clearance in September 2024, creating a basis for selling its caries diagnostic aid in the United States. It also exported Qscan Plus to GSK Consumer Healthcare, now Haleon, in 2019.

The U.S. sales base is now held through a 100%-owned subsidiary, giving the company direct control over local sales. If clearances translate into sales, they could reduce the limits of a Korea-centered revenue structure.

Revenue growth and liquidity recovery

Revenue for 2025 reached KRW 3.4 billion, up 46.2% from 2024, extending growth in the top line. Over the same period, advertising costs fell from the prior year, indicating some improvement in the selling expense structure.

According to a corporate information provider, the current ratio recovered to 79.5% in 2025 from 53.5% in 2024. Simultaneous growth in sales and improved short-term liquidity is cited as a bullish factor.

06

Bear factors

Capital impairment and debt burden

With the capital impairment unresolved, total liabilities of KRW 8.6 billion, combined with negative equity, weigh heavily on financial stability. Interest expense rose from 2024, adding to financing costs that widened the net loss. If capital raising is delayed, the pace of business expansion could be constrained.

Overseas expansion costs front-loaded

A Seoul Credit Rating & Information technical report and company materials attribute the operating loss partly to building a U.S. sales network and rising advertising spend. For 2024, the increase in overseas sales network, U.S. advertising and R&D costs was cited as the cause of wider losses.

The point at which overseas revenue exceeds these costs is difficult to gauge from current disclosures. If costs are recognized before revenue follows, short-term earnings pressure could persist.

Thin float and concentrated ownership

Market capitalization of about KRW 6.7 billion is small, and trading value on November 11, 2026 was recorded at 220,780 won. The largest shareholder holds 36.65%, while foreign ownership is around 0.28%. The single-day move of 11.11% reflects high price volatility. A limited free float can amplify price moves when supply and demand shift.

07

Risk factors

Policy and reimbursement

Reimbursement criteria and eligibility under National Health Insurance can change with policy revisions. Dental insurance expansion is seen as an opportunity, but adjustments to coverage rules could weaken the revenue base.

Overseas clearances are also subject to country-specific regulatory review and sales approval conditions, which can shift timelines.

Capital and financing

With negative equity, the outcome of rights offerings or other external funding directly affects business continuity. Total equity at end-2025 was KRW -6.1 billion and total liabilities KRW 8.6 billion. The timing of the KOSDAQ transfer listing could also change depending on listing requirements and funding plans.

Market liquidity

As a KONEX-listed company with small trading value, market capitalization stood at KRW 6.7 billion on November 11, 2026. In thinly traded stocks, small buy or sell orders can move prices significantly. The high largest-shareholder stake of 36.65% also limits the effective free float and can amplify price swings.

08

Overall view

Aiobio's revenue grew to KRW 3.4 billion in 2025, and operating loss narrowed, but net loss widened to KRW 5.3 billion. Expanded health insurance coverage and U.S. FDA Class II clearance are bullish factors that broaden the product's formal institutional base.

Conversely, total equity of KRW -6.1 billion at end-2025 and total liabilities of KRW 8.6 billion remain the largest bearish factors on the balance sheet.

Overseas sales network and advertising costs are cited as drivers of near-term losses, and whether they convert into revenue can be gauged from future quarterly results.

Market indicators of a KRW 2,400 share price, KRW 6.7 billion market capitalization and 220,780 won trading value reflect the trading profile of a small KONEX stock. Capital raising and the KOSDAQ transfer listing are key milestones for balance sheet improvement. Overall, the picture is one where the direction of business expansion and financial capacity are intertwined.

09

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 6 more articles and sources
  1. comp.fnguide.com
  2. kind.krx.co.kr
  3. kind.krx.co.kr
  4. m.news.nate.com
  5. incruit.com
  6. thevc.kr

Report written 2026-11-11 · Data as of 2026-11-10

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis